Back to top

oncology-screening: Archive

Ahan Chakraborty

How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?

LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.

LLYPositive Net Change AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change

Debanjana Dey

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.

FLGTNegative Net Change PRPONegative Net Change